Physician profile
Adeeb Haroon
NPI 1073186250
$2,270.21
in general payments reported to CMS, 2019-2025
11 companies · $1,083 in 2025
The $1,083 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $44.41 · 2024: $1,142 · 2025: $1,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,989 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $219 · Travel and Lodging: $62.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,989.10 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $218.61 |
| Travel and Lodging | $62.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $492.14 | 2023-2024 | Siliq, Arazlo, Altreno |
| Ucb, INC. | $408.25 | 2025 | Bimzelx |
| Janssen Biotech, INC. | $279.63 | 2024-2025 | Tremfya |
| Janssen Scientific Affairs, LLC | $273.74 | 2024-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $190.43 | 2024 | |
| Incyte Corporation | $157.92 | 2024-2025 | Opzelura |
| Abbvie INC. | $152.99 | 2024 | |
| Genzyme Corporation | $111.40 | 2025 | |
| Arcutis Biotherapeutics, INC. | $93.67 | 2025 | Zoryve |
| Galderma Laboratories, L.P. | $92.20 | 2025 | Nemluvio |
| Takeda Pharmaceuticals U.S.A., INC. | $17.84 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adeeb Haroon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.